Advances in cancer research

1.2k papers and 93.5k indexed citations i.

About

The 1.2k papers published in Advances in cancer research in the last decades have received a total of 93.5k indexed citations. Papers published in Advances in cancer research usually cover Molecular Biology (603 papers), Oncology (416 papers) and Immunology (241 papers) specifically the topics of Virus-based gene therapy research (103 papers), Immunotherapy and Immune Responses (91 papers) and Cancer-related Molecular Pathways (83 papers). The most active scholars publishing in Advances in cancer research are Paul B. Fisher, Devanand Sarkar, Swadesh K. Das, Luni Emdad and Saverio Bettuzzi.

In The Last Decade

Fields of papers published in Advances in cancer research

Since Specialization
EngineeringComputer SciencePhysics and AstronomyMathematicsEarth and Planetary SciencesEnergyEnvironmental ScienceMaterials ScienceChemical EngineeringChemistryAgricultural and Biological SciencesVeterinaryDecision SciencesArts and HumanitiesBusiness, Management and AccountingSocial SciencesPsychologyEconomics, Econometrics and FinanceHealth ProfessionsDentistryMedicineBiochemistry, Genetics and Molecular BiologyNeuroscienceNursingImmunology and MicrobiologyPharmacology, Toxicology and Pharmaceutics

This network shows the specialization of papers published in Advances in cancer research. Nodes represent fields, and links connect fields that are likely to share authors.

Countries where authors publish in Advances in cancer research

Since Specialization
Total citations of papers

This map shows the geographic distribution of research published in Advances in cancer research. It shows the number of citations received by papers published by authors working in each country. You can also color the map by specialization and compare the number of papers published in Advances in cancer research with the expected number of papers based on a country's size and research output (numbers larger than one mean the country's share of papers is larger than expected).

Rankless by CCL
2025